
    
      This study propose to treat patients with metastatic and hormone-refractory prostatic cancer
      in first intention. There is no limits of age from 18 years old. A new inhibitor of
      angiogenesis (Sorafenib) is associated to the standard treatment in this type of pathology.

      Patients have to demonstrate radiologically a disease progression and also a progression
      based on increase of psa level.

      The main objective is to Determine the recommended dose of BAY 43-9006 in combination with
      docetaxel in hormone-refractory prostate cancer patients as first line treatment in patients
      with metastatic hormone-refractory prostate cancer.
    
  